The Mpox Vaccine Hesitancy Scale for Mpox: Links with Vaccination Intention among Men Who Have Sex with Men in Six Cities of China.

Ying Gao, Shangbin Liu, Huifang Xu, Ying Wang, Gang Xu, Fan Hu, Jiechen Zhang, Yong Cai
Author Information
  1. Ying Gao: Public Health Department, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. ORCID
  2. Shangbin Liu: Public Health Department, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  3. Huifang Xu: Public Health Department, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  4. Ying Wang: Public Health Department, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  5. Gang Xu: School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  6. Fan Hu: Public Health Department, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  7. Jiechen Zhang: Dermatology Department, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
  8. Yong Cai: Public Health Department, Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Abstract

BACKGROUND: Vaccine hesitancy is a significant barrier to achieving high vaccination rates, particularly among men who have sex with men (MSM), a group at increased risk for Mpox. This study aimed to develop and validate a Mpox vaccine hesitancy scale specifically tailored for Chinese MSM, grounded in the protection motivation theory (PMT).
METHODS: An online survey through snowball sampling was conducted from October 2023 to March 2024, collecting 2403 valid responses across six representative regions in China. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) were conducted to evaluate the scale's construct validity, while reliability was assessed using Cronbach's �� coefficient. The predictive validity of the scale was analyzed using Receiver Operating Characteristic (ROC) analysis.
RESULTS: EFA ultimately retained 22 items in the Mpox vaccination scale and identified four distinct dimensions: Maladaptive Rewards (seven items), Self-efficacy (seven items), Response Efficacy (four items), and Response Costs (four items). These dimensions were confirmed by CFA, which demonstrated satisfactory model fit indices (����/df = 4.382, RMSEA = 0.053, SRMR = 0.048, GFI = 0.935, CFI = 0.967, NFI = 0.958, TLI = 0.963, and IFI =0.967). All indices were within acceptable ranges. The scale exhibited good internal consistency, with a Cronbach's alpha of 0.906, and strong content validity, with an S-CVI/Ave of 0.952. The scale's predictive accuracy was evaluated using Receiver Operating Characteristic (ROC) analysis. When used to evaluate the scale's predictive accuracy, it yielded an area under the curve (AUC) of 0.854 after adjustments, indicating good predictive ability between high and low hesitancy.
CONCLUSIONS: This scale provides a reliable and valid tool for assessing Mpox vaccine hesitancy among MSM and can be used to gauge Mpox vaccination intention within this group.

Keywords

References

  1. Vaccines (Basel). 2023 Jan 21;11(2): [PMID: 36851118]
  2. J Microbiol Immunol Infect. 2022 Oct;55(5):787-794 [PMID: 35970757]
  3. Vaccines (Basel). 2024 Mar 20;12(3): [PMID: 38543965]
  4. Psychooncology. 2018 Feb;27(2):442-449 [PMID: 28749603]
  5. Saudi Med J. 2024 Aug;45(9):1002-1003 [PMID: 39218470]
  6. Clin Exp Vaccine Res. 2023 Jul;12(3):193-208 [PMID: 37599804]
  7. Vaccines (Basel). 2023 Aug 15;11(8): [PMID: 37631936]
  8. BMC Public Health. 2024 Jan 2;24(1):35 [PMID: 38166776]
  9. Emerg Infect Dis. 2024 May;30(5):916-925 [PMID: 38573160]
  10. Clin Infect Dis. 2024 Jan 23;: [PMID: 38262167]
  11. J Addict Res Ther. 2013 Jul 8;4:154 [PMID: 24478933]
  12. Res Nurs Health. 2006 Oct;29(5):489-97 [PMID: 16977646]
  13. Hum Vaccin Immunother. 2016 May 3;12(5):1155-63 [PMID: 27078191]
  14. SSM Popul Health. 2018 Nov 15;7:005-5 [PMID: 30581956]
  15. Front Public Health. 2024 Mar 27;12:1349514 [PMID: 38601500]
  16. Pathogens. 2022 Nov 01;11(11): [PMID: 36365036]
  17. Int J Addict. 1983 Apr;18(3):393-405 [PMID: 6874160]
  18. MethodsX. 2023 Dec 04;12:102512 [PMID: 38149291]
  19. PLoS One. 2023 Jun 8;18(6):e0286322 [PMID: 37289746]
  20. J Psychol. 1975 Sep;91(1):93-114 [PMID: 28136248]
  21. Soc Sci Med. 2019 Jul;233:87-92 [PMID: 31195194]
  22. Clin Infect Dis. 2023 Apr 17;76(8):1508-1512 [PMID: 36546646]
  23. MMWR Morb Mortal Wkly Rep. 2022 Jun 10;71(23):764-769 [PMID: 35679181]
  24. Euro Surveill. 2022 Jul;27(27): [PMID: 35801519]
  25. BMJ. 2022 Aug 9;378:o1978 [PMID: 35944916]
  26. Curr Opin Immunol. 2021 Aug;71:89-91 [PMID: 34271335]
  27. Trop Med Infect Dis. 2023 Sep 26;8(10): [PMID: 37888585]
  28. Pathogens. 2022 Oct 28;11(11): [PMID: 36364999]
  29. Lancet. 2023 Jan 7;401(10370):60-74 [PMID: 36403582]
  30. J Clin Epidemiol. 2007 Jan;60(1):34-42 [PMID: 17161752]
  31. J Epidemiol Glob Health. 2023 Jun;13(2):226-238 [PMID: 37119512]
  32. Tumour Virus Res. 2021 Dec;12:200222 [PMID: 34175495]
  33. J Med Virol. 2023 Dec;95(12):e29320 [PMID: 38102917]
  34. Lancet Infect Dis. 2022 Dec;22(12):e349-e358 [PMID: 36116460]
  35. Philos Trans R Soc Lond B Biol Sci. 2014 May 12;369(1645):20130433 [PMID: 24821919]
  36. Front Public Health. 2022 Oct 25;10:997637 [PMID: 36388271]

Grants

  1. GWVI-11.1-29/Key discipline projects of Shanghai Three-Year Action Plan for Public Health under Grant
  2. Grant No. Z155080000004/national health commission of the PRC
  3. TR2023rc11/Tongren Hospital Talent Launch Project
  4. TR2024RC10/Tongren Hospital Talent Launch Project
  5. CNKW2022Y08/Changning District Medical and Health Research Special Project

Word Cloud

Created with Highcharts 10.0.00Mpox=scaleitemshesitancyvaccinationmenanalysisvaliditypredictiveamongMSMscale'susingfourVaccinehighsexgroupvaccineprotectionmotivationtheoryconductedvalidChinafactorEFACFAevaluatereliabilityCronbach'sReceiverOperatingCharacteristicROCsevenResponseindices967withingoodaccuracyusedintentionMenBACKGROUND:significantbarrierachievingratesparticularlyincreasedriskstudyaimeddevelopvalidatespecificallytailoredChinesegroundedPMTMETHODS:onlinesurveysnowballsamplingOctober2023March2024collecting2403responsesacrosssixrepresentativeregionsExploratoryconfirmatoryconstructassessed��coefficientanalyzedRESULTS:ultimatelyretained22identifieddistinctdimensions:MaladaptiveRewardsSelf-efficacyEfficacyCostsdimensionsconfirmeddemonstratedsatisfactorymodelfit����/df4382RMSEA053SRMR048GFI935CFINFI958TLI963IFI=0acceptablerangesexhibitedinternalconsistencyalpha906strongcontentS-CVI/Ave952evaluatedyieldedareacurveAUC854adjustmentsindicatingabilitylowCONCLUSIONS:providesreliabletoolassessingcangaugeHesitancyScaleMpox:LinksVaccinationIntentionSexSixCities

Similar Articles

Cited By